Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.

Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.

Gen Z is changing the game when it comes to investing as the stock market is not just for experienced investors anymore.

Fortinet (NASDAQ: FTNT) stock has been in scintillating form on the stock market over the past six months, rising a ...

In this podcast, Motley Fool analysts Ron Gross and Jason Moser and host Dylan Lewis discuss: What the jobs report and the ...

Billed as the 'Model T-iki,' the temporary menu has Polynesian cocktails and cuisine with a Motown twist, all through a ...

The reason you invest is so that you can withdraw in the future. Learn how to determine a sustainable withdrawal rate for ...

Warren Buffett's famous value investing philosophy is why he bought shares in companies ranging from American Express to ...

Traveling doesn’t have to come with a hefty price tag. It’s something someone with an open mind to learning can achieve with ...

A report from the KZN Department of Health reveals that medication stock levels at healthcare facilities are at 80%, prompting discussions on management practices and supply chain efficiency ...

As Vermont’s oldest continuously operated independent bookstore, it’s been feeding the minds of locals and visitors alike ...

The Australian market has been navigating a period of economic adjustment, highlighted by the Reserve Bank of Australia's recent interest rate cut, which reflects ongoing debates about inflation and ...